1. A108 USTEKINUMAB IV INDUCTION RESULTS IN CROHN'S DISEASE SYMPTOM IMPROVEMENT WITHIN THE FIRST WEEK IN ANTI-TNF REFRACTORY PATIENTS. (1st March 2018) Authors: Sandborn, W; Yeager, B; Gasink, C; Hoops, T; Gao, L; Wang, Y; Jacobstein, D; Lee, S D; Hanauer, S Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 2 Page Start: 165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY. (21st February 2022) Authors: Panaccione, R; Danese, S; Zhouwen, W; Pangan, A; Hébuterne, X; Nakase, H; D'Haens, G; Panes, J; Lindsay, J; Higgins, P; Loftus, E; Sandborn, W; Xie, W; Sanchez gonzalez, Y; Liu, J; Weinreich, M; Vermeire, S Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 5(2022)Supplement 1 Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY. (21st February 2022) Authors: Panaccione, R; Ferrante, M; Feagan, B G; Sandborn, W; Panes, J; Peyrin-Biroulet, L; Colombel, J; Schreiber, S; Dubinsky, M; Baert, F; Hisamatsu, T; Neimark, E; Huang, B; Liao, X; Song, A; Berg, S; Duan, W; Pang, Y; Pivorunas, V; Kligys, K Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 5(2022)Supplement 1 Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A80 ENDOSCOPIC HEALING WITH USTEKINUMAB IN CROHN'S DISEASE: THE UNITI ENDOSCOPY SUB-STUDY. (1st March 2018) Authors: Feagan, B G; Sandborn, W; Gasink, C; Chan, D; Lang, Y; Pollack, P; Hanauer, S; Wolf, D; Jacobstein, D; Johanns, J; Szapary, P; Rutgeerts, P Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 1 Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE–SEVERE CROHN'S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY. (1st March 2018) Authors: Sands, B E; Gasink, C; Jacobstein, D; Gao, L; Johanns, J; Szapary, P; Colombel, J F; Targan, S; Ghosh, S; Sandborn, W Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 1(2018)Supplement 1 Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. AODWE-006 Efficacy of ustekinumab for induction and maintenance of histological healing in patient's with crohn's disease. (17th June 2017) Authors: Li, K; Chan, D; Pollack, P; Jacobstein, D; Brodmerkel, C; Gasink, C; Feagan, B; Sandborn, W; Rutgeerts, P; Hertogh, G De Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. DOP05 Target engagement and pharmacodynamic biomarker analysis following treatment with the oral gut-targeted HIF-1α stabilizer GB004 in a Phase 1b trial in Active Ulcerative Colitis. (27th May 2021) Authors: Sandborn, W; Ding, Z; Osterhout, R; Feagan, B; Danese, S; Jucov, A; Bhandari, B R; Raghupathi, K; Olson, A; Van Biene, C; Ford, J; Aranda, R; Levesque, B G; Bruey, J M Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S043 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn's disease: Pharmacokinetic findings from VISIBLE 2. (15th January 2020) Authors: Chen, C; Rosario, M; Polhamus, D; Dirks, N; Zhang, W; Sun, W; Kisfalvi, K; Feagan, B; Sandborn, W; Vermeire, S; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S056 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. DOP53 Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis. (25th January 2019) Authors: Sandborn, W; Nguyen, D; Ferslew, B; Hao, L-Y; Kanno, T; Tomsho, L; Boyle, D; Graham, R; Abhyankar, B; Panes, J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S060 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. DOP76 Corticosteroid sparing effects of ustekinumab therapy for ulcerative colitis through 2 years: UNIFI long-term extension. (15th January 2020) Authors: Peyrin-Biroulet, L; Sandborn, W; Sands, B; Scherl, E; Marano, C; O'Brien, C; Zhang, H; Johanns, J; Zhou, Y; Abreu, M; Arasaradnam, R P; Rowbotham, D S; Leong, R W L; Danese, S Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗